Published in Mol Cancer Ther on October 16, 2012
TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene (2013) 1.51
The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res (2014) 1.25
MiR-200c and HuR in ovarian cancer. BMC Cancer (2013) 1.18
The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget (2015) 1.18
The role of microRNAs in ovarian cancer. Biomed Res Int (2014) 1.15
MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res (2013) 1.14
MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. PLoS One (2013) 1.00
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene (2013) 0.92
MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis (2014) 0.92
MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. PLoS One (2013) 0.87
Application of microRNA in diagnosis and treatment of ovarian cancer. Biomed Res Int (2014) 0.86
The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol (2015) 0.84
Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis. J Transl Med (2014) 0.82
Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1. Int J Clin Exp Pathol (2015) 0.81
Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget (2015) 0.81
Suppression of choriocarcinoma invasion and metastasis following blockade of BDNF/TrkB signaling. Cancer Med (2013) 0.81
Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett (2015) 0.79
Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res Ther (2015) 0.78
An integrated network of microRNA and gene expression in ovarian cancer. BMC Bioinformatics (2015) 0.78
The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer. J Ovarian Res (2015) 0.78
miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition. Front Pharmacol (2016) 0.77
Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer. Front Nutr (2015) 0.77
Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs. Mol Cells (2015) 0.77
MicroRNAs in Gynecological Cancers: Small molecules with big implications. Cancer Lett (2017) 0.76
Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep (2013) 0.76
Hybrid-polymerase chain reaction to identify novel target genes of miR-134 in paclitaxel resistant human ovarian carcinoma cells. Oncol Lett (2015) 0.76
Research Progress of MicroRNA in Early Detection of Ovarian Cancer. Chin Med J (Engl) (2015) 0.75
Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer. Int J Mol Sci (2017) 0.75
Prioritizing cancer-related microRNAs by integrating microRNA and mRNA datasets. Sci Rep (2016) 0.75
Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison. Hum Pathol (2016) 0.75
Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. Am J Cancer Res (2017) 0.75
MicroRNA-200c as a prognostic and sensitivity marker for platinum chemotherapy in advanced gastric cancer. Oncotarget (2017) 0.75
MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocr Relat Cancer (2017) 0.75
The miR-200 family in ovarian cancer. Oncotarget (2017) 0.75
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res (2008) 5.54
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature (2004) 4.53
Ovarian cancer. Lancet (2009) 3.95
Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer (2010) 3.84
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther (2009) 2.50
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol (2009) 2.26
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res (2005) 2.21
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol (2011) 2.21
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res (2007) 2.12
Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 2.06
On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res (2009) 1.88
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol (2010) 1.80
Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res (2011) 1.74
The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer (2010) 1.73
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res (2007) 1.56
Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol (2009) 1.54
Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch (2006) 1.49
Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol (2009) 1.44
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol (2007) 1.41
Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci (2008) 1.24
Microtubules: a dynamic target in cancer therapy. IUBMB Life (2008) 1.24
Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome. Cancer Lett (2009) 1.21
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol (2012) 1.15
Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol (2008) 1.09
TrkB as a therapeutic target for ovarian cancer. Expert Opin Ther Targets (2009) 0.99
Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. Int J Oncol (2006) 0.97
Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol (2010) 0.94
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol (2011) 0.92
Potential mechanisms of resistance to microtubule inhibitors. Semin Oncol (2008) 0.88
Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology (2009) 0.85
Current status of maintenance therapy for advanced ovarian cancer. Int J Womens Health (2010) 0.77
[Anoikis-suppression and invasion induced by tyrosine kinase receptor B in OVCAR3 ovarian cancer cells]. Zhonghua Fu Chan Ke Za Zhi (2008) 0.77
Regulation of inflammatory responses by IL-17F. J Exp Med (2008) 5.56
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol (2007) 3.13
Managing conflicts of interest in the conduct of clinical trials. JAMA (2002) 3.01
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol (2011) 2.88
Case records of the Massachusetts General Hospital. Case 4-2009. A 39-year-old pregnant woman with fever after a trip to Africa. N Engl J Med (2009) 2.72
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer (2012) 2.59
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther (2009) 2.50
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res (2006) 2.38
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res (2006) 1.84
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84
CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol (2002) 1.83
Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res (2011) 1.74
Type-specific cell line models for type-specific ovarian cancer research. PLoS One (2013) 1.73
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol (2003) 1.72
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res (2008) 1.67
Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control (2009) 1.66
Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol (2012) 1.63
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer (2010) 1.61
Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma. Cancer Prev Res (Phila) (2010) 1.60
Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl Cancer Inst (2012) 1.58
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol (2004) 1.58
Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer (2014) 1.55
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol (2005) 1.50
Catalytic direct arylation with aryl chlorides, bromides, and iodides: intramolecular studies leading to new intermolecular reactions. J Am Chem Soc (2006) 1.49
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol (2008) 1.49
The pathology milestones and the next accreditation system. Arch Pathol Lab Med (2014) 1.48
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer (2010) 1.46
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res (2006) 1.43
Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res (2006) 1.43
Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab (2004) 1.41
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol (2004) 1.32
Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol (2012) 1.32
ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol (2008) 1.32
Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A (2009) 1.28
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol (2004) 1.28
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther (2006) 1.26
The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia (2012) 1.25
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol (2005) 1.23
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer (2009) 1.23
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res (2008) 1.18
MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer (2010) 1.18
Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res (2009) 1.17
Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol (2006) 1.17
Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst (2009) 1.16
microRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.14
Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol (2005) 1.11
Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res (2005) 1.10
Functional regulation of oestrogen receptor pathway by the dynein light chain 1. EMBO Rep (2005) 1.10
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol (2007) 1.09
New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem (2002) 1.08
Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res (2010) 1.07
AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res (2008) 1.07
Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg (2004) 1.07
Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol (2005) 1.06
Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology (2005) 1.06
Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer (2013) 1.06
Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res (2008) 1.05
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther (2010) 1.04
Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila) (2011) 1.04
Ablation of Indian hedgehog in the murine uterus results in decreased cell cycle progression, aberrant epidermal growth factor signaling, and increased estrogen signaling. Biol Reprod (2010) 1.03
Generation of a Mig-6 conditional null allele. Genesis (2007) 1.03
miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLoS One (2012) 1.02
Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol (2008) 1.02
Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther (2009) 1.02
Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab (2004) 1.02
Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest (2013) 1.01
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol (2012) 1.01
Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat (2008) 1.01
S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling. Lab Invest (2009) 1.00